UroMems Secures $60 Million Investment to Revolutionize Treatment for Urinary Incontinence

UroMems Secures $60 Million Investment for SUI Treatment

UroMems, a pioneering company in the field of implantable mechatronic technology, recently announced a substantial strategic investment of $60 million, marking its most significant funding round to date. This investment, entirely financed by Ajax Health Fund I, will primarily support pivotal clinical trials and the preparations necessary for the commercial launch of its groundbreaking UroActive® System, specifically designed for the treatment of stress urinary incontinence (SUI).

Driving Innovation in Urinary Incontinence Solutions

The UroActive® System is notable for being the first smart automated artificial urinary sphincter (AUS). This innovative device aims to address the challenge of SUI, which affects millions of individuals worldwide—approximately 40 million Americans and 90 million Europeans. The condition can severely impact one's quality of life, leading to psychological challenges such as depression and social stigma.

Funding from Ajax Health will enable UroMems to accelerate its ongoing clinical trials, specifically the SOPHIA2 clinical study, being conducted across 21 investigational centers in the United States and France. Data from these trials will be essential for obtaining regulatory approval in various global markets, paving the way for the UroActive® System's commercial debut.

A Partnership for Success

David Beylik, a partner at Ajax Health, expressed enthusiasm about this investment round, emphasizing the critical role of collaboration with potential industry leaders to foster innovative medical technology. By joining forces with UroMems, Ajax Health seeks to enhance patient care and standards for evaluating and treating SUI.

The funding will also enable UroMems to build on momentum generated from its earlier successful round of investment—$47 million in Series C funding led by Crédit Mutuel Innovation in June 2024, which saw participation from notable entities such as the European Innovation Council and various venture capital partners.

Philippe Boucheron from Bpifrance, one of the existing investors, echoed the excitement, describing Ajax Health's addition to the project as beneficial for UroActive’s journey towards market readiness. He highlighted the potential that the innovative device holds, spurred by positive early clinical trial outcomes and significant interest from healthcare professionals.

Transformative Technology for Patients

The UroActive® System distinguishes itself with a MyoElectroMechanical System (MEMS) that seamlessly accommodates the patient’s activity without requiring manual adjustments. This design aims to enhance user convenience and improve the overall quality of life for patients living with SUI. UroMems has consistently met vital development milestones, underscoring its commitment to advancing medtech while delivering tangible benefits to patients and practitioners alike.

As UroMems gears up for the next phase, including an FDA PMA submission and subsequent commercialization efforts, the company has expressed gratitude for the valuable partnership with Ajax Health. Hamid Lamraoui, co-founder and CEO of UroMems, envisions the UroActive® System as a transformative solution, addressing the significant unmet needs of patients facing urinary incontinence.

Upcoming Changes to the Board

To further enhance governance and direction, both David Beylik and Dr. Jeremy Durack are set to join UroMems' board of directors. Beylik brings a wealth of experience from his previous role as COO of Maverix Medical and legal experience from his time at Latham & Watkins LLP. Dr. Durack, who specializes in interventional radiology and holds expertise in minimally invasive urological procedures, will bolster the company's strategic direction within the medical field.

In conclusion, UroMems’ latest funding not only marks a milestone for the company but also sets a promising course for innovative treatment solutions in the medical technology landscape, reassuring many that better options for managing stress urinary incontinence are on the horizon.